BIOMAT Database Logo BIOMAT Database Logo

Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. 2021

Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Department of Basic Science, Higher Technological Institute, 10th of Ramadan City 228, Egypt.

Vascular endothelial growth factor-2 (VEGFR-2) is considered one of the most important factors in tumor angiogenesis, and consequently a number of anticancer therapeutics have been developed to inhibit VEGFR-2 signaling. Accordingly, eighteen derivatives of thieno[2,3-d]pyrimidines having structural characteristics similar to VEGFR-2 inhibitors were designed and synthesized. Anticancer activities of the new derivatives were assessed against three human cancer cell lines (HCT-116, HepG2, and MCF-7) using MTT. Sorafenib was used as positive control. Compounds 17c-i, and 20b showed excellent anticancer activities against HCT-116 and HepG2 cell lines, while compounds 17i and 17g was found to be active against MCF-7 cell line. Compound 17f exhibited the highest cytotoxic activities against the examined cell lines, HCT-116 and HepG2, with IC50 values of 2.80 ± 0.16 and 4.10 ± 0.45 µM, respectively. Aiming at exploring the mechanism of action of these compounds, the most active cytotoxic derivatives were in vitro tested for their VEGFR-2 inhibitory activity. Compound 17f showed high activity against VEGFR-2 with an IC50 value of 0.23 ± 0.03 µM, that is equal to that of reference, sorafenib (IC50 = 0.23 ± 0.04 µM). Molecular docking studies also were performed to investigate the possible binding interactions of the target compounds with the active sites of VEGFR-2. The synthesized compounds were analyzed for their ADMET and toxicity properties. Results showed that most of the compounds have low to very low BBB penetration levels and they have non-inhibitory effect against CYP2D6. All compounds were predicted to be non-toxic against developmental toxicity potential model except compounds 17b and 20b.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors.
January 2021, Bioorganic & medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors.
December 2017, Bioorganic & medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
New application of novel tetrazine derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
September 2022, Future medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
June 2023, European journal of medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
October 2014, European journal of medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold.
July 2011, Bioorganic & medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
April 2022, European journal of medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of novel pyrrolo [2,3-d] pyrimidine derivatives as potent FAK inhibitors based on cyclization strategy.
October 2023, Bioorganic chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.
December 2022, European journal of medicinal chemistry,
Souad A El-Metwally, and Mohsen M Abou-El-Regal, and Ibrahim H Eissa, and Ahmed B M Mehany, and Hazem A Mahdy, and Hazem Elkady, and Alaa Elwan, and Eslam B Elkaeed
Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
July 2023, European journal of medicinal chemistry,
Copied contents to your clipboard!